S. P. Anthony

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris et al. · European Journal of Cancer · 2012 · 131 citations

Pro-drug Sf1126, Medicine, Pharmacology +8

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

S. P. Anthony, Igor Puzanov, Peck‐Sun Lin et al. · Journal of Clinical Oncology · 2011 · 22 citations

Immunology, Molecular Biology, Pharmacotherapy +25

506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

Jasgit C. Sachdev, Hendrick-Tobias Arkenau, J. R. Infante et al. · European Journal of Cancer · 2014 · 13 citations

Potent Inhibitor, Medicine, Pharmacology +9

Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3- kinase (PI3K) inhibitor in patients with solid tumors

Ulrich Schwertschlag, E. Gabriela Chiorean, S. P. Anthony et al. · Journal of Clinical Oncology · 2008 · 13 citations

Solid Tumors, Iv Infusion, Pharmacotherapy +16